Jasper Therapeutics, Inc. (JSPR) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$0.47

From 52W high−77.38%

Volume392238.00

Market cap$15.43M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$0.47

From 52W high

−77.38%

Volume

392238.00

Market cap

$15.43M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.3x

P/E (TTM)

—

RSI (14)

38.1

MomentumView details →

1D Return

−3.40%

YTD Return

−73.71%

SummaryUpdated Jun 1, 2026

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company founded in 2020 and based in Redwood City, California. The company specializes in developing innovative therapeutic agents for hematopoietic stem cell transplantation and gene therapies, with a focus on conditioning agents and stem cell engineering technologies. Since going public in January 2020, Jasper has been advancing its pipeline of experimental treatments designed to expand the use of stem cell transplantation and improve outcomes for patients requiring these life-saving procedures.

Ask drillr about Jasper Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

10.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−2248.48%

ROA (TTM)

−269.20%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+73.54%

FCF YoY

+18.31%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+19.22%

EBITDA YoY

+66.01%

MomentumView details →

1D Return

−3.40%

YTD Return

−73.71%

1Y Return

−75.33%

RSI (14)

38.1

vs 50D SMA

−18.19%

vs 200D SMA

−42.46%

Capital & dividendView details →

Debt/Equity

0.19x

Current Ratio

1.47x

Quick Ratio

1.47x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.10

EPS Surprise

62.66%

Beats (12Q)

6/12

Next Q EPS Est

−$0.30

Avg Surprise (4Q)

23.64%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−31.77M

Op. CF (TTM)

−60.33M

Next earningsNov 9, 2026 →

Latest newsMore news →

Jasper Therapeutics announced a 1-for-30 reverse stock split of its common stock.4h ago

Jasper Therapeutics completed enrollment in the IgA nephropathy cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104).20d ago

Similar companies

Hoth Therapeutics, Inc.HOTH Citius Pharmaceuticals, Inc.CTXR Acumen Pharmaceuticals, Inc.ABOS Tevogen Bio Holdings Inc.TVGNW Bolt Biotherapeutics, Inc.BOLT NewcelX Ltd.NCEL Find similar companies →

Latest newsMore news →

Jasper Therapeutics announced a 1-for-30 reverse stock split of its common stock.4h ago Jasper Therapeutics completed enrollment in the IgA nephropathy cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104).20d ago